Matches in SemOpenAlex for { <https://semopenalex.org/work/W2791774604> ?p ?o ?g. }
Showing items 1 to 57 of
57
with 100 items per page.
- W2791774604 abstract "TPS18 Background: In the phase Ib KEYNOTE-012 study, the anti–PD-1 antibody pembro demonstrated promising antitumor activity and acceptable safety as monotherapy in pretreated patients (pts) with PD-L1+ mTNBC. Adding pembro to chemo may enhance antitumor activity. KEYNOTE-355 (NCT02819518) is a global phase III study of pembro+chemo vs PBO+chemo in pts with previously untreated, locally recurrent, inoperable TNBC/mTNBC. Methods: Eligible pts are ≥18 y and have centrally confirmed, locally recurrent, inoperable TNBC or mTNBC not previously treated with chemo (prior chemo in [neo]adjuvant setting is allowed); measurable disease per RECIST v1.1; ECOG PS 0-1; ≥6 mo between definitive surgery or last dose of adjuvant chemo, whichever was last; and first disease recurrence (≥12 mo if prior treatment with same-class agent). Part 1 is an open-label, unblinded safety run-in of ~30 pts in 3 arms (pembro+nab-paclitaxel, pembro+paclitaxel, pembro+gemcitabine/carboplatin). Part 2 is a double-blind, PBO-controlled study of ~828 pts randomized 2:1 to pembro 200 mg every 3 weeks + chemo (nab-paclitaxel 100 mg/m 2 on d 1, 8, and 15 every 28 d; paclitaxel 90 mg/m 2 on d 1, 8, and 15 every 28 d; or gemcitabine 1000 mg/m 2 + carboplatin AUC 2 on d 1 and 8 every 21 d) or PBO+chemo. Crossover is not allowed. Stratification factors are study chemo (taxane vs gemcitabine/carboplatin), tumor PD-L1 expression (+/-), and prior therapy with same-class agent in the (neo)adjuvant setting (yes/no). Treatment will occur for ≤35 administrations (pembro/PBO only) or until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or decision to discontinue. Primary end points are safety in part 1 and PFS (by RECIST v1.1, central radiology review) and OS in part 2; secondary end points include ORR (by RECIST v1.1, central radiology review) and duration of response. AEs will be graded per NCI CTCAE v4.0. Response will be assessed at wk 8, 16, 24, then at 9-wk intervals up to 1 y, and at 12-wk intervals thereafter. Interim safety analysis will occur after pts complete 1 treatment cycle in part 1. Clinical trial information: NCT02819518." @default.
- W2791774604 created "2018-03-29" @default.
- W2791774604 creator A5033494478 @default.
- W2791774604 creator A5051629490 @default.
- W2791774604 creator A5053678097 @default.
- W2791774604 creator A5077520870 @default.
- W2791774604 date "2018-02-10" @default.
- W2791774604 modified "2023-09-23" @default.
- W2791774604 title "KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)." @default.
- W2791774604 doi "https://doi.org/10.1200/jco.2018.36.5_suppl.tps18" @default.
- W2791774604 hasPublicationYear "2018" @default.
- W2791774604 type Work @default.
- W2791774604 sameAs 2791774604 @default.
- W2791774604 citedByCount "6" @default.
- W2791774604 countsByYear W27917746042018 @default.
- W2791774604 countsByYear W27917746042019 @default.
- W2791774604 countsByYear W27917746042020 @default.
- W2791774604 countsByYear W27917746042021 @default.
- W2791774604 crossrefType "journal-article" @default.
- W2791774604 hasAuthorship W2791774604A5033494478 @default.
- W2791774604 hasAuthorship W2791774604A5051629490 @default.
- W2791774604 hasAuthorship W2791774604A5053678097 @default.
- W2791774604 hasAuthorship W2791774604A5077520870 @default.
- W2791774604 hasConcept C121608353 @default.
- W2791774604 hasConcept C126322002 @default.
- W2791774604 hasConcept C143998085 @default.
- W2791774604 hasConcept C2776694085 @default.
- W2791774604 hasConcept C2777701055 @default.
- W2791774604 hasConcept C2777863537 @default.
- W2791774604 hasConcept C2778239845 @default.
- W2791774604 hasConcept C2780057760 @default.
- W2791774604 hasConcept C2780110267 @default.
- W2791774604 hasConcept C2780258809 @default.
- W2791774604 hasConcept C2781451048 @default.
- W2791774604 hasConcept C530470458 @default.
- W2791774604 hasConcept C71924100 @default.
- W2791774604 hasConceptScore W2791774604C121608353 @default.
- W2791774604 hasConceptScore W2791774604C126322002 @default.
- W2791774604 hasConceptScore W2791774604C143998085 @default.
- W2791774604 hasConceptScore W2791774604C2776694085 @default.
- W2791774604 hasConceptScore W2791774604C2777701055 @default.
- W2791774604 hasConceptScore W2791774604C2777863537 @default.
- W2791774604 hasConceptScore W2791774604C2778239845 @default.
- W2791774604 hasConceptScore W2791774604C2780057760 @default.
- W2791774604 hasConceptScore W2791774604C2780110267 @default.
- W2791774604 hasConceptScore W2791774604C2780258809 @default.
- W2791774604 hasConceptScore W2791774604C2781451048 @default.
- W2791774604 hasConceptScore W2791774604C530470458 @default.
- W2791774604 hasConceptScore W2791774604C71924100 @default.
- W2791774604 hasLocation W27917746041 @default.
- W2791774604 hasOpenAccess W2791774604 @default.
- W2791774604 hasPrimaryLocation W27917746041 @default.
- W2791774604 hasRelatedWork W2345415641 @default.
- W2791774604 isParatext "false" @default.
- W2791774604 isRetracted "false" @default.
- W2791774604 magId "2791774604" @default.
- W2791774604 workType "article" @default.